Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
117.46
+0.06 (+0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
71
72
Next >
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
October 23, 2023
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
October 22, 2023
The companies studied a combination of Keytruda and Padcev in bladder cancer patients.
Via
Investor's Business Daily
3 Safe Dividend Stocks to Beat Inflation
October 21, 2023
Higher prices make things tougher for consumers and companies alike. Some corporations, however, are capable of pushing through this headwind.
Via
The Motley Fool
Looking At Merck & Co's Recent Unusual Options Activity
October 19, 2023
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
October 19, 2023
Via
Benzinga
9 Analysts Have This to Say About Merck & Co
October 04, 2023
Via
Benzinga
How Is The Market Feeling About Merck & Co?
October 02, 2023
Via
Benzinga
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
October 23, 2023
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
October 20, 2023
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon.
Via
Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
Via
Benzinga
7 Healthcare Stocks to invest in for a Healthy Future
October 20, 2023
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.
Via
InvestorPlace
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...
Via
Benzinga
Exposures
Product Safety
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need.
October 16, 2023
Merck has a slew of in-progress products in its pipeline and pays a decent dividend. So, consider shoring up your portfolio with MRK stock.
Via
InvestorPlace
7 Safe Stocks to Steady Your Portfolio in 2024
October 15, 2023
With circumstances in the market applying the jitters, concerned investors may want to play these safe stocks to buy.
Via
InvestorPlace
Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients
October 10, 2023
Merck & Co Inc (NYSE: MRK) reported topline data from the Phase 3 KEYNOTE-671 trial investigating Keytruda, Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable...
Via
Benzinga
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 10, 2023
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging.
Via
Benzinga
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
October 09, 2023
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.
Via
Talk Markets
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’
October 09, 2023
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories
October 05, 2023
CNBC Disney Slashes Children's Ticket Prices Amid Attendance Slump
Via
Benzinga
Exposures
COVID-19
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
October 05, 2023
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant...
Via
Benzinga
No Merck's COVID-19 Pill - US Government Ceases Free Distribution
October 05, 2023
The U.S. government is set to cease the distribution of free doses of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral treatment Lagevrio (molnupiravir), by mid-November, shifting its availability to...
Via
Benzinga
Exposures
COVID-19
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
October 04, 2023
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.
Via
Investor's Business Daily
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
October 04, 2023
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock.
Via
Benzinga
2 Magnificent Growth Stocks to Buy Right Now
October 04, 2023
These two biotech stocks could be big winners for patient investors.
Via
The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
October 03, 2023
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...
Via
Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
October 03, 2023
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 02, 2023
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.